2.5 Outcome definitions
Our composite end-point outcomes consisted of the incidence of DSA,
chronic lung allograft
dysfunction (CLAD), and mortality. Serum samples were routinely
collected post-transplantation to screen for the presence of anti-human
leukocyte antigen (HLA) antibodies. The presence of DSA was determined
by comparing the measured HLA types with donor HLA typing. CLAD was
defined as a 20% decline from the best post-transplant FEV1 according
to the International Society of Heart and Lung Transplant
Guidelines.20 Additionally, we examined the
distribution characteristics of TAC exposure, represented by average
C0 and IPV, across 3 distinct time periods (0–3 months,
3–12 months and 12–24 months).